<DOC>
	<DOCNO>NCT00003427</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining one drug may kill tumor cell . PURPOSE : Phase I trial study effectiveness oxaliplatin plus irinotecan treating patient previously treat metastatic gastrointestinal cancer respond previous treatment .</brief_summary>
	<brief_title>Oxaliplatin Plus Irinotecan Treating Patients With Metastatic Gastrointestinal Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) combination chemotherapy regimen oxaliplatin plus irinotecan drug give week four week , follow two week rest , patient metastatic gastrointestinal cancer . II . Evaluate toxicity combination chemotherapy administer manner . III . Determine pharmacokinetics platinum irinotecan MTD combination chemotherapy patient population . OUTLINE : This dose escalation study . Patients receive oxaliplatin IV 120 minute , immediately follow irinotecan IV 30 minute , weekly 4 week ( day 1 , 8 , 15 , 22 ) . Courses repeat every 42 day . Treatment continue absence unacceptable side effect disease progression . Sequential dose escalation oxaliplatin follow sequential dose escalation irinotecan . Dose escalation cohort 3-6 patient continue maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxic effect . Patients follow approximately every 2-3 month . PROJECTED ACCRUAL : A total 2-36 patient accrue study within 18-36 month .</detailed_description>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Liver Neoplasms</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Gastrointestinal Neoplasms</mesh_term>
	<mesh_term>Bile Duct Neoplasms</mesh_term>
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Gallbladder Neoplasms</mesh_term>
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Malignant Carcinoid Syndrome</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic gastrointestinal carcinoma Measurable disease No CNS metastases No obstruction partial obstruction GI tract No obstruction genitourinary tract PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 70100 % Life expectancy : Not specify Hematopoietic : WBC least 3,500/mm3 Neutrophil count least 1,500/mm3 Platelet count least 125,000/mm3 Hepatic : Bilirubin le 1.5 mg/dL Renal : Creatinine great 1.5 mg/dL Cardiovascular : No uncontrolled high blood pressure , unstable angina , active congestive heart failure , myocardial infarction within prior 6 month , serious uncontrolled cardiac arrhythmia Neurological : No concurrent symptomatic peripheral sensory neuropathy Other : No active uncontrolled infection Not pregnant nursing Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior cisplatin , oxaliplatin , nitrosoureas , mitomycin C 1 2 prior chemotherapy regimen allow ( include irinotecan ) Endocrine therapy : Not specify Radiotherapy : No prior radiation therapy whole pelvis , 30 % great bone marrow , site measurable disease At least 4 week since prior radiation therapy recover Surgery : Not specify</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>stage IV colon cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>recurrent pancreatic cancer</keyword>
	<keyword>stage IV rectal cancer</keyword>
	<keyword>recurrent colon cancer</keyword>
	<keyword>recurrent rectal cancer</keyword>
	<keyword>stage IV anal cancer</keyword>
	<keyword>recurrent anal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>metastatic gastrointestinal carcinoid tumor</keyword>
	<keyword>recurrent gastrointestinal carcinoid tumor</keyword>
	<keyword>advanced adult primary liver cancer</keyword>
	<keyword>recurrent adult primary liver cancer</keyword>
	<keyword>unresectable gallbladder cancer</keyword>
	<keyword>recurrent gallbladder cancer</keyword>
	<keyword>unresectable extrahepatic bile duct cancer</keyword>
	<keyword>recurrent extrahepatic bile duct cancer</keyword>
	<keyword>recurrent small intestine cancer</keyword>
	<keyword>stage IV pancreatic cancer</keyword>
</DOC>